• British Skin Foundation

• Dental implants
• Implant failure
• Implant prognosis
• Implant stability
• Implant success
• Implant survival
• Osseointegration

• Humans
• Dental Implants
• Prognosis
• Osseointegration/physiology
• Dental Restoration Failure
• Dental Implantation, Endosseous
• Risk Factors

• Capillary permeability
• Hypoxia-inducible factor 1
• Menstruation
• Prostaglandin receptor
• Prostaglandins F

• Female
• Animals
• Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
• Endometrium/metabolism
• Dinoprost/metabolism
• Dinoprost/analogs & derivatives
• Mice
• Receptors, Prostaglandin/metabolism
• Receptors, Prostaglandin/genetics
• Menstruation/metabolism
• Vascular Endothelial Growth Factor A/metabolism
• Vascular Endothelial Growth Factor A/genetics

• 81571410 National Natural Science Foundation of China
• 2023GJZD01 Non-profit Central Research Institute Fund of the National Research Institute for Family Planning

• Analgesic
• Pancreas
• Pancreatic fistula

• Pancreaticoduodenectomy/adverse effects
• Humans
• Pancreatic Fistula/etiology
• Pancreatic Fistula/epidemiology
• Postoperative Complications/epidemiology
• Postoperative Complications/etiology
• Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
• Risk Factors
• Cyclooxygenase Inhibitors/therapeutic use
• Cyclooxygenase Inhibitors/adverse effects
• Length of Stay/statistics & numerical data

• dental implant failure rate
• dental implants
• medically compromised patients
• osseointegration
• systemic disorders

• antineoplastic agents
• drug repositioning
• etodolac
• imatinib
• leuprolide
• mebendazole
• medical oncology
• metformin
• multimorbidity
• propranolol

• COX-2
• NSAIDs
• anti-inflammation
• contrast agent
• magnetic resonance imaging

• RS-2023-00207902 National Research Foundation of Korea

• acute kidney injury
• proteomics
• kidney biopsy
• nsaid

• Pregnancy
• Humans
• Female
• Adult
• Proteome
• Cesarean Section
• Proteomics
• Kidney/pathology
• Acute Kidney Injury/pathology
• Fibrosis
• Renal Insufficiency, Chronic/pathology
• Anti-Inflammatory Agents

• K08 DK123411 NIDDK NIH HHS
• U01 DK114908 NIDDK NIH HHS

• Alveolarization
• Angiogenesis
• Bronchopulmonary dysplasia
• Cell cycle arrest
• Lung inflammation
• Nonsteroidal anti-inflammatory drug
• Pulmonary arterial hypertension

• Andrographis paniculata
• andrographolide
• angiogenesis
• p-ERK
• post-operative wound

• apoptosis
• autophagy
• colorectal cancer
• non-steroidal anti-inflammatory drugs
• photodynamic therapy
• phthalocyanine

Wound treatment comprises a substantial portion of the healthcare budgets in developed countries. Studies suggest that about 50% of patients admitted to hospitals have wounds, while 1%−2% of the general population in the developed world suffers from chronic wounds. Chronic wounds fail to repair themselves within the expected period of 30 days. Technologies have been developed to address challenges encountered during wound care with the aim of alleviating pain, promoting healing, or controlling wound infections.

The objective of this study was to explore the technological improvements that have been made in this field over time.

To gain insight into the future of wound management, a systematic review of literature on the subject was conducted in scientific databases (PubMed, Scopus, Web of Science, Medline, and Clinical Trials).

Results indicate that wound dressings have evolved from the traditional cotton gauze to composite materials embedded with appropriate ingredients such as metal‐based nanoparticles. Studies on biodegradable dressing materials are also underway to explore their applicability in dressing large and irregular wounds. On the other hand, conventional drugs and traditional formulations for the management of pain, inflammation, infections, and accelerating healing have been developed. However, more research needs to be carried out to address the issue of microbial resistance to drugs. Drugs for managing other ailments also need to be designed in such a way that they can augment wound healing. In addition, it has been demonstrated that a coordinated integration of conventional and traditional medicine can produce laudable results in chronic wound management.

Accordingly, collaborative efforts and ingenuity of all players in the field can accelerate technological advances in the wound care market to the benefit of the patients.

Wounds affect about 50% of patients admitted to hospitals.

Technologies have been developed including biodegradable dressing materials to address underlying challenges.

Technological advancement, rising incidences of chronic wounds, growing government support, and a rising elderly population will drive wound market growth.

A careful combination of recent research outputs can greatly change wound care technologies.

This review highlights the recent research advances and opportunities in the wound care field.

The future lies in biodegradable dressing materials, probably embedded with selected nanoparticles and which shall be combined in predetermined ratios.

Eucommiae Folium (EF), a traditional Chinese medicine, has been used to treat secondary hypertension, including renal hypertension and salt-sensitive hypertension, as well as hypertension caused by thoracic aortic endothelial dysfunction, a high-fat diet, and oxidized low-density lipoprotein. The antihypertensive components of EF are divided into four categories: flavonoids, iridoids, lignans, and phenylpropanoids, such as chlorogenic acid, geniposide acid and pinoresinol diglucoside. EF regulates the occurrence and development of hypertension by regulating biological processes, such as inhibiting inflammation, regulating the nitric oxide synthase pathway, reducing oxidative stress levels, regulating endothelial vasoactive factors, and lowering blood pressure. However, its molecular antihypertensive mechanisms are still unclear and require further investigation. In this review, by consulting the relevant literature on the antihypertensive effects of EF and using network pharmacology, we summarized the active ingredients and pharmacological mechanisms of EF in the treatment of hypertension to clarify how EF is associated with secondary hypertension, the related components, and underlying mechanisms. The results of the network pharmacology analysis indicated that EF treats hypertension through a multi-component, multi-target and multi-pathway mechanism. In particular, we discussed the role of EF targets in the treatment of hypertension, including epithelial sodium channel, heat shock protein70, rho-associated protein kinase 1, catalase, and superoxide dismutase. The relevant signal transduction pathways, the ras homolog family member A (RhoA)/Rho-associated protein kinase (ROCK) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase/eNOS/NO/Ca²⁺ pathways, are also discussed.

•

Eucommiae Folium (EF) treats secondary hypertension via the RhoA/ROCK1 and NO/sGC/cGMP pathways.

• Gastric ulcer
• Indomethacin
• Mesenchymal stem cells
• Proliferating cell nuclear antigen
• Vascular endothelial growth factors

• Angiogenesis
• Cardiovascular disease
• Cell Biology
• Hypoxia
• Nitric oxide

• Animals
• Apoptosis Regulatory Proteins/deficiency
• Apoptosis Regulatory Proteins/genetics
• Astrocytes/pathology
• Astrocytes/physiology
• Cyclooxygenase 2/genetics
• Cyclooxygenase 2/metabolism
• Disease Models, Animal
• Disease Progression
• Endothelial Cells/metabolism
• Hemangioma, Cavernous, Central Nervous System/etiology
• Hemangioma, Cavernous, Central Nervous System/pathology
• Hemangioma, Cavernous, Central Nervous System/physiopathology
• Human Umbilical Vein Endothelial Cells
• Humans
• Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
• Kruppel-Like Factor 4
• Kruppel-Like Transcription Factors/genetics
• Kruppel-Like Transcription Factors/metabolism
• Mice
• Mice, Knockout
• Models, Neurological
• Mutation
• Nitric Oxide/biosynthesis
• Nitric Oxide Synthase Type III/genetics
• Nitric Oxide Synthase Type III/metabolism
• RNA, Messenger/genetics
• RNA, Messenger/metabolism
• Vascular Endothelial Growth Factor A/biosynthesis

• K01 HL133530 NHLBI NIH HHS
• P30 NS047101 NINDS NIH HHS
• T32 HL086344 NHLBI NIH HHS
• P01 HL151433 NHLBI NIH HHS
• R25 HL145817 NHLBI NIH HHS
• T32 HL007444 NHLBI NIH HHS
• S10 OD010417 NIH HHS
• R35 HL139947 NHLBI NIH HHS
• P01 NS092521 NINDS NIH HHS
• R01 NS121070 NINDS NIH HHS
• National Institute of Neurological Disorders and Stroke
• National Heart, Lung, and Blood Institute

Metronomic therapy is characterized by drug administration in a low-dose, repeated, and regular manner without prolonged drug-free interval. The two main anticancer mechanisms of metronomic therapy are antiangiogenesis and immunomodulation, which have been demonstrated in several delicate in vitro and in vivo experiments. In contrast to the traditional maximum tolerated dose (MTD) dosing of chemotherapy, metronomic therapy possesses comparative efficacy but greatlydecreases the incidence and severity of treatment side-effects. Clinical trials of metronomic anticancer treatment have revealed promising results in a variety cancer types and specific patient populations such as the elderly and pediatric malignancies. Oral cavity squamous cell carcinoma (OCSCC) is an important health issue in many areas around the world. Long-term survival is about 50% in locally advanced disease despite having high-intensity treatment combined surgery, radiotherapy, and chemotherapy. In this article, we review and summarize the essence of metronomic therapy and focus on its applications in OCSCC treatment.

• metronomic
• oral cancer
• oral squamous cell carcinoma

Colorectal cancer (CRC) is graded as one of the most common cancer. It accounts for the second leading cause of cancer deaths worldwide. The present study intends to investigate the role and importance of different biochemical variables in the development of colorectal cancer.

In this cross-sectional study we recruited ninety-one patients diagnosed with colorectal cancer and fifty-three age-sex matched controls from June 2017 to June 2018. Different variables i.e. SOD, GSH, CAT, MDA, TGF, VEGF, TNF, ILs, MMPs, etc., were estimated with the help of their respective methods. Our findings suggest a significant increase in the levels of different inflammatory and stress-related markers. The NFκB, TGF-β, VEGFβ, 8OHdG, IsoP-2α were significantly found to be increased in patients with colon cancer (0.945 ± 0.067 μg/ml, 18.59 ± 1.53 pg/ml, 99.35 ± 4.29 pg/ml, 21.26 ± 1.29 pg/ml, 102.25 ± 4.25 pg/ml) as compared to controls (0.124 ± 0.024 μg/ml, 8.26 ± 0.88 pg/ml, 49.58 ± 2.62 pg/ml, 0.93 ± 0.29 pg/ml, 19.65 ± 3.19 pg/ml). Notably, the levels of different antioxidants were shown to be significantly lower in patients of colon cancer. The present study concluded that excessive oxidative stress and lipid peroxidation result in a decrease in the antioxidative capacity of cells which may influence diverse signaling cascades including NF-KB, which results in DNA modification and gene transcription that ultimately involved in the progression of colon cancer.

• C-reactive protein
• COX-2
• Malondialdehyde (MDA)
• inflammation
• isoprostanes
• tumor necrosis factor-alpha (TNF-a)

• Analgesics
• Anastomotic leakage
• non-steroidal anti-inflammatory drugs
• pancreatic fistula
• pancreaticoduodenectomy
• postoperative complications

• cancer
• cyclooxygenase
• obstructive apneas
• prostaglandin E2
• prostaglandin receptors
• sleep

This study aimed to examine the effects of wet-to-dry bandages for the treatment of surgical wounds in goats.

Three types of bandages, i.e., the calcium alginate gel, the homogenous platelet-rich plasma (PRP) gel dressing, and saline dressing, were used to promote the healing process for the management of wounds. Artificial circular wounds were created and treated with bandages to evaluate their effects on the wound healing process in 12 goats. The morphological parameters, i.e., diameters (cm), duration of healing, and wound contraction (cm), were evaluated to differentiate the postoperative sequelae on wound healing process up to day 30 in three different treatment groups of goats. Tissue specimens from the wounds were examined histopathologically on 1st, 3rd, 7th, and 30th postoperative days. Finally, the obtained data were analyzed using the Statistical Package for the Social Sciences 19 software.

The current study revealed that the contraction diameter was higher in calcium alginate gel and PRP gel treated group when compared to the saline dressing group. Aggregation of immunoreactive cells (neutrophils, macrophages, and lymphocytes), collagen fiber bundles among the cells, and proliferation of blood vessels were observed in the epidermis of calcium alginate gel, PRP gel treated and saline dressing wounds, which promote the healing process of wounds. In visual inspection, the number of reactive cells and proliferation of blood vessels were higher in the calcium alginate gel and PRP gel treated group than the saline dressing.

In terms of epithelialization, epidermal characteristics, neovascularization, and infiltration of immunoreactive cells, the calcium alginate gel and the homogenous PRP gel dressings showed the best healing performance. Therefore, the present study suggests that clinicians could consider the calcium alginate gel dressing and homogenous PRP gel dressing as beneficial for wound care.

• Bandages
• goat
• histological evaluation
• surgical wound

Patients suffering from tissue ischemia, who would greatly benefit from angiogenesis-promoting therapies such as hypoxia preconditioned blood-derived secretomes commonly receive oral anticoagulation (OA) and/or have diabetes mellitus (DM). In this study, we investigated the effect of OA administration on the in vitro angiogenic potential of hypoxia preconditioned plasma (HPP) and serum (HPS), prepared from nondiabetic/diabetic subjects who did not receive OA (n = 5) or were treated with acetylsalicylic acid (ASA, n = 8), ASA + clopidogrel (n = 10), or nonvitamin K antagonist oral anticoagulants (n = 7) for longer than six months. The effect of DM was differentially assessed by comparing HPP/HPS obtained from nondiabetic (n = 8) and diabetic (n = 16) subjects who had not received OA in the past six months. The concentration of key proangiogenic (vascular endothelial growth factor or VEGF) and antiangiogenic (thrombospondin-1 or TSP-1 and platelet factor-4 or PF-4) protein factors in HPP/HPS was analyzed via ELISA, while their ability to induce microvessel formations was examined in endothelial cell cultures. We found that OA use significantly reduced VEGF levels in HPP, but not HPS, compared to non-OA controls. While HPP and HPS TSP-1 levels remained largely unchanged as a result of OA usage, HPS PF-4 levels were significantly reduced in samples obtained from OA-treated subjects. Neither OA administration nor DM appeared to significantly reduce the ability of HPP or HPS to induce microvessel formations in vitro. These findings indicate that OA administration does not limit the angiogenic potential of hypoxia preconditioned blood-derived secretomes, and therefore, it does not prohibit the application of these therapies for supporting tissue vascularization and wound healing in healthy or diabetic subjects.

• COX-1
• NOACs
• VEGF
• acetylsalicylic acid
• angiogenesis
• blood-derived therapy
• clopidogrel
• drug anticoagulation
• hypoxia
• hypoxia preconditioned plasma
• hypoxia preconditioned serum
• oral anticoagulation
• peripheral blood cells

Engrailed variant-2 (EN2) has been suggested as a potential diagnostic biomarker; however, its presence and functional role in prostate cancer (PCa) cells is still controversial or unknown. Here, we analyzed 1) the expression/secretion profile of EN2 in five independent samples cohorts from PCa patients and controls (prostate tissues and/or urine) to determine its utility as a PCa biomarker; and 2) the functional role of EN2 in normal (RWPE1) and tumor (LNCaP/22Rv1/PC3) prostate cells to explore its potential value as therapeutic target. EN2 was overexpressed in our two cohorts of PCa tissues compared to control and in tumor cell lines compared with normal-like prostate cells. This profile was corroborated in silico in three independent data sets [The Cancer Genome Atlas(TCGA)/Memorial Sloan Kettering Cancer Center (MSKCC)/Grasso]. Consistently, urine EN2 levels were elevated and enabled discrimination between PCa and control patients. EN2 treatment increased cell proliferation in LNCaP/22Rv1/PC3 cells, migration in RWPE1/PC3 cells, and PSA secretion in LNCaP cells. These effects were associated, at least in the androgen-sensitive LNCaP cells, with increased AKT and androgen-receptor phosphorylation levels and with modulation of key cancer-associated genes. Consistently, EN2 treatment also regulated androgen-receptor activity (full-length and splicing variants) in androgen-sensitive 22Rv1 cells. Altogether, this study demonstrates the potential utility of EN2 as a non-invasive diagnostic biomarker for PCa and provides novel and valuable information to further investigate its putative utility to develop new therapeutic tools in PCa.

• aggressiveness
• biomarker
• engrailed homeobox variants
• prostate cancer

• Animals
• Cornea/blood supply
• Cornea/metabolism
• Cornea/pathology
• Corneal Neovascularization/etiology
• Corneal Neovascularization/genetics
• Corneal Neovascularization/metabolism
• Cyclooxygenase 2/genetics
• Disease Models, Animal
• Disease Susceptibility
• Female
• Gene Expression
• Male
• Rats
• Rats, Inbred F344
• Rats, Inbred Strains
• Rats, Sprague-Dawley
• Rats, Wistar
• Receptors, Androgen/metabolism
• Receptors, Estrogen/metabolism
• Sex Characteristics
• Species Specificity
• Vascular Endothelial Growth Factor A/genetics
• Vascular Endothelial Growth Factor Receptor-1/genetics
• Vascular Endothelial Growth Factor Receptor-2/genetics

• National Health and Medical Research Council

Previously, Aznar et al., showed that Daple/CCDC88C enables Wnt receptors to transactivate trimeric G-proteins during non-canonical Wnt signaling via a novel G-protein binding and activating (GBA) motif. By doing so, Daple serves two opposing roles; earlier during oncogenesis it suppresses neoplastic transformation and tumor growth, but later it triggers epithelial-to-mesenchymal-transition (EMT). We have identified and characterized two isoforms of the human Daple gene. While both isoforms cooperatively suppress tumor growth via their GBA motif, only the full-length transcript triggers EMT and invasion. Both isoforms are suppressed during colon cancer progression, and their reduced expression carries additive prognostic significance. These findings provide insights into the opposing roles of Daple during cancer progression and define the G-protein regulatory GBA motif as one of the minimal modules essential for Daple’s role as a tumor suppressor.

A number of recent studies have been published evaluating the chemopreventive effect of aspirin against gastric cancer, and an updated meta‐analysis is required to evaluate this relationship further. This study presents a meta‐analysis of studies examining the effect of aspirin on gastric cancer incidence and death.

The PUBMED and Cochrane Central Registration of Controlled Trials databases were searched for eligible studies published up to December 2018. Pooled risk ratios for gastric cancer incidence and death in aspirin users versus nonusers were determined using fixed‐ and random‐effects models. The influence of the frequency of aspirin use, duration of aspirin use, and geographic location on gastric cancer incidence was evaluated.

The meta‐analysis comprised 33 studies with a total of 1 927 971 patients. The pooled risk ratios for gastric cancer incidence in the fixed‐ and random‐effects models were 0.890 (95% confidence interval, 0.871–0.909) and 0.826 (0.740–0.922), respectively. In Asia and North America, the maximum preventive benefit of aspirin use was observed with weekly or daily use. Aspirin use was most effective for noncardiac gastric cancer. The pooled risk ratios for gastric cancer death in the fixed‐ and random‐effects models were 0.798 (0.749–0.850) and 0.894 (0.780–1.024), respectively. Significant heterogeneity was observed among studies of gastric cancer incidence but not gastric cancer death.

Aspirin use may reduce the risk of gastric cancer incidence and death; however, the relationship may be limited to a specific frequency and duration of aspirin use and geographic location.

• aspirin
• gastric cancer death
• gastric cancer incidence

• Allium sp
• E-cadherin
• Garlic
• cyclooxygenase 2
• gastric cancer

• Postpartum involution
• Semaphorin 7a
• collagen
• cyclooxygenase-2
• metastasis
• postpartum breast cancer

• cox-2
• vegf
• tumor microenvironment
• pancreatic cancer

• Animals
• Cell Line, Tumor
• Cyclooxygenase 2 Inhibitors/metabolism
• Disease Models, Animal
• Female
• Humans
• Mice
• Pancreatic Neoplasms/metabolism
• Pancreatic Neoplasms/pathology
• Tumor Microenvironment
• Vascular Endothelial Growth Factor A/metabolism

• U54 CA210181 NCI NIH HHS
• F31 CA196033 NCI NIH HHS
• T32 CA136515 NCI NIH HHS
• R01 CA192381 NCI NIH HHS
• K12 CA138464 NCI NIH HHS

• Antibiotic-impregnated polymethylmethacrylate beads
• Antibiotics
• Equine
• Intraosseous perfusion
• Regional limb perfusion
• Wounds

• 1,8-Naphthalimides
• Amonafide
• Anticancer agents
• DNA intercalators
• Mitonafide

• Angiogenesis
• CINCA
• Prostaglandin E
• Skin ulcer
• Wound healing

• Alprostadil/therapeutic use
• Cryopyrin-Associated Periodic Syndromes/complications
• Female
• Humans
• Inflammasomes
• Interleukin-1beta
• Skin Ulcer/complications
• Skin Ulcer/drug therapy

• Angiogenesis Inhibitors/chemistry
• Angiogenesis Inhibitors/isolation & purification
• Angiogenesis Inhibitors/pharmacology
• Animals
• Bevacizumab/pharmacology
• Chick Embryo
• Chorioallantoic Membrane/blood supply
• Chorioallantoic Membrane/drug effects
• Magnoliopsida/chemistry
• Molecular Structure
• Neovascularization, Physiologic/drug effects
• Plant Extracts/chemistry
• Plant Extracts/isolation & purification
• Plant Extracts/pharmacology
• Plant Leaves/chemistry
• Structure-Activity Relationship
• Triterpenes/chemistry
• Triterpenes/isolation & purification
• Triterpenes/pharmacology

• colorectal cancer
• inflammation
• intestinal microbiology
• prognosis
• prognostic biomarker

• Aging
• Akt, serine threonine kinase signaling protein
• Angiogenesis
• BrdU, bromodeoxyuridine
• EC, endothelial cell
• Endothelial Cells
• FITC, fluorescein isothiocyanate
• GEC, gastric mucosal microvascular endothelial cells isolated from rats
• GU, gastric ulcer
• Gene Therapy
• LV-GFP, lentiviral green fluorescent protein
• LV-NGF, lentiviral nerve growth factor
• NGF, nerve growth factor
• NSAID, nonsteroidal anti-inflammatory drug
• Nerve Growth Factor
• PBS, phosphate-buffered saline
• PCNA, proliferating cell nuclear antigen
• PCR, polymerase chain reaction
• PI3, phosphoinositide-3
• SRF, serum response factor
• Ulcer Healing
• VEGF, vascular endothelial growth factor
• mRNA, messenger RNA
• mTOR, mammalian target of rapamycin
• siRNA, small interfering RNA

• I01 BX000626 BLRD VA

• Ketorolac
• NSAIDs
• Pancreaticoduodenectomy
• Postoperative pancreatic fistula